[Hengrui Medicine: Hatrombopag ethanolamine tablets approved for two new indications] On September 10, Hengrui Medicine (600276.SH) announced that the company received a notice from the State Food and Drug Administration, approving two new indications for the independently developed Class 1 innovative drug Hatrombopag ethanolamine tablets, which are adult patients with thrombocytopenia caused by chemotherapy for solid tumors, and children with chronic primary immune thrombocytopenia ≥ 6 years old who have previously had poor response to glucocorticoids, immunoglobulins and other treatments. This approval makes this product the first thrombopoietin receptor agonist approved for CTIT indication in the world, and the first independently developed oral TPO-RA in the field of ITP for children in China. Up to now, the cumulative R&D investment in projects related to this product is approximately 658 million yuan.